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Mulberry (Morus alba L., Moraceae) is one of the most valuable and rich in phytochemicals plant. 
Morusin is a prenylated flavonoid present in mulberry roots and leaves. The in vitro antibacterial activity of 
morusin and its interactions with conventional antibiotics (oxacillin, amoxicillin and gentamicin) were 
evaluated against four methicillin resistant Staphylococcus aureus clinical isolates (MRSA T1 – T4) with 
resistance to oxacillin and cefoxitin which had been isolated from dogs with various pathologies. Minimum 
inhibitory concentrations (MICs) were determined by the microdilution method. The interactions were 
assessed by the chequerboard method - with interpretation through fractional inhibitory concentration index 
(FICI) and isobologram analysis. The interactions were confirmed by the time-kill assay. MICs varied 
between 3.125 and 6.25µg/mL for morusin alone against all four MRSA clinical isolates. Chequerboard 
method showed synergies for the combinations: morusin – oxacillin (FICI=0.024 - 0.27), morusin – 
amoxicillin (FICI=0.024 - 0.27) and morusin - gentamicin (FICI=0.05 - 0.12) against all four tested isolates. 
Time-kill assay determined synergies for the following combinations: morusin – oxacillin against MRSA T1, 
morusin – amoxicillin against MRSA T2 and morusin - gentamicin against all four isolates. Our preliminary 
study evaluated the antibacterial activity of morusin and its ability to act synergistically with antibiotics; 
these results suggest that morusin might be a promising strategy to overcome antibiotic resistence. 




Mulberry (Morus alba L., Moraceae) is one of the most valuable and rich in 
phytochemicals plant. Mulberry leaves are used for feeding silkworms due to the high content of 
proteins (1). Numerous reviews have been published on both in vitro and in vivo studies that 
assessed antidiabetic, antioxidant, anticancer, hypolipidemic, antiatherogenic and anti- 
inflammatory activities of mulberry (2 - 4). Mulberry extracts and their isolated compounds 
showed antimicrobial potential against harmful pathogens: Bacilllus subtilis, Staphylococcus 
aureus, Streptococcus faecalis and Mycobacterium smegmatis (5 - 8). Morusin (fig. 1) is a 
prenylated flavonoid isolated from the root and leaves of mulberry with antibacterial activity 
against Gram-positive bacteria (9). 
The post-antibiotic apocalypse due to the frequent and improper use of antibiotics involves 
new strategy in overcoming antibiotic resistance (10). Methicillin resistant S. aureus (MRSA) is 




cephalosporins, aminoglycosides, macrolides, fluoroquinolones, but also to other important 
antibiotics such as glycopeptides (vancomycin and teicoplanin) (11). 
A promising strategy in overcoming antibiotic resistance is the synergy between vegetal 
products and conventional antibiotics (12). 
The present preliminary study aimed to assess the antibacterial activity and the interactions 












Material and methods 
Minimum inhibitory concentrations (MICs) of oxacillin (OX), amoxicillin (Amx), 
gentamicin (Gn) and morusin (MO) were determined by the microdilution method against four 
MRSA clinical isolates according to the Clinical & Laboratory Standards Institute (CLSI) (13) and 
European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines (14). The 
sources of all clinical isolates resistant to cefoxitin and oxacillin were infections (recurrent otitis, 
pyoderma and laryngopharyngitis) in dogs. 
The interactions between MO and antibiotics were determined using the chequerboard 





FICI = FICAntibiotic + FICMorusin where: 






= M ICMorusin in combination with antibiotic . 
MICMorusin alone 
 
A combination is synergistic if FICI value ≤ 0.5, additive when it is > 0.5 and ≤1, 
indifferent when it is 1 – 4, and antagonistic when it is > 4 (16). 
Graphical representation of experimental dose-response surface and theoretical dose- 
response surface of interaction were performed according to Bliss independence–based model. 
Experimental dose-response surface (Emeasured) represents the experimental percentage of growth in 
the presence of different concentrations of MO and/or antibiotics. Epredicted is the calculated 
percentage of growth based on the experimental percentage of growth according to Bliss 
independence–based model, taking into account the non-interactive process between two 
components. The difference between predicted (Epredicted) and measured (Emeasured) dose-response 
surface is the theoretical dose-response surface of interaction (ΔE). A ΔE value above zero 




Time-kill assay was performed in order to confirm the results obtained in the chequerboard 
method. According to the time-kill assay, synergy is considered if the decrease in the viable colony 
count ≥ 2log10 CFU/mL; the combination is evaluated in comparison to the count obtained with the 
most active single component, after 24 or 48 hours. The antagonism is defined as an increase in the 
colony count of ≥ 2log10 CFU/mL, the combination being compared to the count obtained with the 
most active single component of combination after 24 or 48 hours (16). 
 
Results and discussion 
MIC values of MO alone against four MRSA clinical isolates varied between 3.125 and 
6.25 µg/mL. The obtained results were in agreement with the already published results. Sohn HY 
et al. have reported MIC values of 5–30 µg/mL for MO against Streptococcus faecalis, S. aureus, 
Mycobacterium smegmatis and Bacillus subtilis (9). Our results confirmed the antibacterial activity 
of MO against Gram-positive bacteria including MRSA strains. 
 
Table 1. In vitro interactions between MO and antibiotics determined by the chequerboard 
method and time-kill assay 
 MRSA T1 MRSA T2 MRSA T3 MRSA T4 
MIC (µg/mL) 
MO 6.25 6.25 3.13 6.25 
 OX combinations 
MIC (µg/mL) 
OX 









MIC ; MIC (µg/mL) 
OX–MO MO–OX 0.50; 0.10 0.50; 0.10 2; 0.78 4; 1.56 
FICI* / TKA** 0.05 (S)/ S 0.024 (S)/ Nc 0.26 (S)/ Nc 0.27 (S)/ Nc 
 Amx combinations 
MIC (µg/mL) 
Amx 









MIC ; MIC (µg/mL) 
Amx–MO MO–Amx 0.50; 0.10 0.50; 0.10 2; 0.78 4; 1.56 
FICI* / TKA** 0.05 (S)/ Nc 0.024 (S)/ S 0.26 (S)/ Nc 0.27 (S)/ Nc 
 Gn combinations 
MIC (µg/mL) 
Gn 









MIC ; MIC (µg/mL) 
Gn–MO MO–Gn 0.02; 0.10 0.02; 0.39 0.02; 0.10 0.03; 0.10 
FICI* / TKA** 0.08 (S)/ S 0.12 (S)/ S 0.06 (S)/ S 0.05 (S)/ S 
Abbreviation: MO – morusin, OX – oxacillin, Amx – amoxicillin, Gn – gentamicin, MICatb–MO – MIC of antibiotic in presence of MO, 
MICMO–atb – MIC of MO in presence of antibiotic; FICI – fractional inhibitory concentration index, S –synergy, Nc– synergy has not 
been confirmed 
*effect of the combination determined through checkerboard method, **effect of the combination determined through time-kill assay, 
¥susceptibility to antibiotic according to European Committee on Antimicrobial Susceptibility - Testing Breakpoint tables for 
interpretation of MICs and zone diameter Version 7.0. Valid from 2017-01-01. 
 
According to the FICI interpretation and isobologram representation (checkerboard 
method), synergy was observed for combinations MO – OX (FICI = 0.024-0.27; fig. 2a), MO – 
Amx (FICI = 0.024-0.27; fig. 2b) and MO – Gn (FICI = 0.05-0.12; fig. 2c) against all four MRSA 




synergy obtained for the combinations MO - Gn against MRSA T4. Table 2 summarizes the results 
























































Figure 2. Interactions between MO – OX (a), MO – Amx (b) and MO – Gn (c) 
against MRSA clinical isolates T1 – T4; 
purple colored dotted circles highlight synergies. 
































Figure 3. Experimental design of the chequerboard method with the exemplification of the 
results obtained for the combination MO - Gn against MRSA T4. 
 
The experimental percentage of growth (fig. 4a) in the presence of different 
concentrations of MO and/or antibiotics and theoretical dose-response surface of 
interaction (fig. 4b) are represented and synergies have been confirmed through Bliss 
independence–based model interpretation. 
 
Figure 4a. Three-dimensional plot of the experimental percentage of growth (Emeasured) between 






Figure 4b. Theoretical dose-response surface of interaction (ΔE) between MO and Gn against 
MRSA T4 (ΔE above zero (positive) indicates synergy). 
 
 
Time-kill assay confirmed the synergy for the combinations MO – OX against MRSA T1 
(fig. 5a) and MO – Amx against MRSA T2 (fig. 5b). The results obtained in the time-kill assay 
method for combinations MO – OX against MRSA T2-T4 and MO – Amx against MRSA T1, 
MRSA T3 and MRSA T4 were not fully in agreement with those observed when using the 
checkerboard method because the logarithmic reductions of the colony-forming units obtained for 
the combinations between MO and antibiotics were not 2log10 lower than the logarithmic 
reductions obtained for the most potent/active component (MO) of the combinations. No increase 
in the viable colony count of more than 2log10 CFU/mL compared to the viable count obtained with 
the most active single agent of combination (MO) was recorded and the antagonism was excluded 
for the combinations MO – OX and MO – Amx against MRSA strains. 
Differences between the results obtained in the checkerboard method and time-kill assay 
have been also reported by other authors (12). These differences can be explained by the difference 
between the measured phenomena - checkerboard method assesses the inhibitory effect while time 
kill assay measures the bactericidal effect. The concordance between the results given by the two 
methods has been estimated as being 44-88% (17). 
In our study, time-kill assay confirmed the synergy for the combination MO – Gn against 
all four clinical isolates: MRSA T1 (fig. 6a and fig. 7a), MRSA T2 (fig. 6b and fig. 7b), MRSA T3 
(fig. 6c and fig. 7c) and MRSA T4 (fig. 6d and fig. 7d), because the logarithmic reductions of the 
colony-forming units obtained for the combination MO - Gn were 2log10 lower than the logarithmic 












































































½ MIC MO (3.125µg/mL) +½ CMI OX (8µg/mL) 
   ½ MIC OX (8µg/mL) 
½ MIC MO (3.125µg/mL) 
Bacterial growth control 
 
Figure 5. Time–kill curves for the combinations MO – OX against MRSA T1 (a) and MO – Amx 















































































½ MIC MO (3.125µg/mL) +½ MIC Gn (0.125µg/mL   ½ MIC MO (3.125µg/mL) +½ MIC Gn (0.125µg/mL) 
   ½ MIC Gn (0.125µg/mL)   ½ MIC Gn (0.125µg/mL) 
½ MIC MO (3.125µg/mL)   ½ MIC MO (3.125µg/mL) 
























0 4h  24h 48h 
Time 0 4h Time 24h 48h 
½ MIC MO (1.56µg/mL) +½ CMI Gn (0.25µg/mL) 
   ½ MIC Gn (0.25µg/mL) 
½ MIC MO (1.56µg/mL) 
Bacterial growth control 
½ MIC MO (3.125µg/mL) +½ MIC Gn (0.5µg/mL) 
   ½ MIC Gn (0.5µg/mL) 
½ MIC MO (3.125µg/mL) 
Bacterial growth control 
Figure 6. Time–kill curves for the combination MO – Gn against MRSA T1 (a), MRSA T2 (b), 
MRSA T1 (c) and MRSA T1 (d). 
a. MO - OX against MRSA T1 b. MO - Amx against MRSA T2 
a. MO - Gn against MRSA T1 b. MO - Gn against MRSA T2 
c. MO - Gn against MRSA T3 
   























































Figure 7. Differences between MO – Gn (1), Gn (2) and MO (3) against MRSA T1 (a), 
MRSA T2 (b), MRSA T3 (c), MRSA T4 (d) in time kill-assay determinations. 
  
c. d. 
Figure 7. Differences between MO – Gn (1), Gn (2) and MO (3) against MRSA T1 (a), MRSA 
T2 (b), MRSA T3 (c), MRSA T4 (d) in time kill-assay determinations (cont.). 
 
Conclusion 
Our study reports on the antibacterial activity of morusin alone against four MRSA clinical 
isolates and its ability to act synergistically with antibiotics. As MRSA has become an increasingly 
global concern, synergy between phytochemicals and conventional antibiotics is a promising 
option to overcome antibiotic resistence. This preliminary study showed that morusin has the 
potential to reverse the bacterial resistence to oxacillin and amoxicillin of MRSA and increase the 
susceptibility of MRSA strains to gentamicin. 
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